<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 162 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page161.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=162">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 162 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 162</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=162"><img src="../thumb/162.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Cardio-Vascular Agents - 7.7.2                                                 2020-04 / 131
       myopathy risk, concom. fluconazole, admin.4 hrs.aft.cholestyramine,   pend.on indicat. Prim.hypercholesterolaem.& combin.(mix.)   a risk fact.predispos.to ren.fail. developm.second.to rhabdomyolys.,
       myotoxic./ musc.pain/weakn./rhabdomyolys.with concom. colchi-  hyperlipidaem: 10 mg once dly. Therap.response within 2 wks.&   haemorrhagic. stroke pts.on entry appear.to be at incr.risk for recurr.
       cine, freq.monit.with concom. warfar./ other coumar.deriv., period.  max.respons achiev.within 4 wks.  haemorrhagic stroke, OC, monit.concom. warfar., allow 1 mnth.interv.
       lipid determinat. & dos.adjustm.accord.to respons., efficacious in   Heterozygous familial hypercholesterolaem in paed.pts.(&gt;10-  aft.discont.ther.bef. plann.pregn.
       monother.or in combinat.with bile acid sequestrants or other resins,   17 yrs.): Init.10 mg dly. Max. recomm.dos.20 mg/day.  Drug interactions: Incr.plasma conc.with protease inhibit./cyto-
       combinat.with nicotin. acid/cholestyram./fibrates in childr.& adolesc.   Homozygous familial hypercholesterolaem: Most pts.re-  chrome P450 3A4/ erythromycin /grapefruit juice, myopathy risk incr.
       not investig., monit.pts.on concom. glibenclimide if fluvastatin dos.  spond to 80 mg.  with concom.immunosuppress.agents incl. cyclospor. /fibric acid deri-
       incr.to 80 mg/day as safety with this combinat.not est.  Reduct.of CV complicats.: Dos.range 10-80 mg once dly.  vat./nicotin.acid/azole antifung. or erythromycin & cytochrome P450,
       Drug interactions: Bioavailabil.reduc.with rifampicin, INR incr.with   Contraindications: Act.liv.dis./persist.unexpl. elev. ser.transami-  incr. AUC with diltiazem, reduc.plasma conc.with P450 3A4 induc.&
       warfarin, cyclosporin incr. AUC & C -max.2-fold.  nas.&gt; 3x ULN, concom.use with rifampicin, diltiazem & grapefruit   oral antacids contain Mg & Al, plasma conc.decr.with colestipol al-
                                     juice, pts.with Child-Pugh B & C (liv.cirrhosis), pregn.& lactat.,
       LESTAVOR, Activo [P/S]        breastfeed., women of childbear.potent.unless adeq. contracept.  though LDL-C reduct. was great.in combin.ther.than when either med
                                                                  was giv.alone, steady-state plasma conc.of digox. incr., AUC values
       Atorvastatin                  precaut.taken.               of norethindrone & ethinyl estradiol incr.
       Indications: Adjunct.to diet & where other non-pharmacolog. meas.  Side effects: Rhabdomyolys.with/without ren. impairm., myalgia,
       inadeq.to reduc.elev.tot.-cholesterol/ LDL-cholestrol/apolipoprot.B &   myopathy, thrombocytopaen., tinnit., GI disords., sinusit., pharyngit.,   NOVATIN, Novagen [P/S]
       triglyceride levs.in prim.hypercholesterolaem. /mix. dyslipidaem.&   pancreatit., asthen., accid.injury, flu syndr., abdom./chest & back pain,   Simvastatin
       heterozygous familial hypercholesterolaem., reduc.tot.-cholesterol   malaise., periph.oed., fatig., hepatit., cholestat. jaund., allerg.reacts.  Indications: Reduct.of elev.ser.tot.cholester.& LDL-cholester.in prim.
       & LDL-cholesterol in homozygous familial hypercholesterolaem.as   incl.anaphylax., tendon rupture, hypo./hyperglycaem., anoxer., weight   hypercholesterolaem./ heterozyg.famil. hyperacholesterolaem./mix.
       adjunct to other lipid low. treatm. or if such treatm.unavail.  gain, hypoaesthes., paraesthes., dizzin., headache, periph.neuropathy,   hyperlipidaem. when respons.to diet & other non pharmacolog.meas.
       (S4) TABS. 44/7.5/1058, 1059, 1060, 1061  amnes., dysgeus., arthralg., myosit., musc.cramps, insomn., impot.,   inadeq., reduc.risk of tot. mortal. by reduc.coron.death/reduc.risk of
       719366-001: 10 mg, 30, R34,00  prurit., rash, alopec, urticar., bullous rash, Stev. John. syndr., tox.epi-  non-fat. MI/ reduc.risk of undergo.myocard. revasculat. proced. &
       719367-001: 20 mg, 30, R36,09  derm.necrolys., erythem. multiforme., infects., cognitive impairm.,   slow.coron.artheroscleros. progress in pts.with coron.heart dis.&
       719368-001: 40 mg, 30, R63,50  immune-mediat. necrotis.myopathy  hypercholesterolaem. unrespons.to diet.
       719369-001: 80 mg, 30, R115,06  Warnings and special precautions: Ther.with lipid low.agents   (S4) TABS. 41/7.5/0382, 0383, 0384
       Dosage: Cholesterol low.diet in place. Dos. determin. indiv.accord.  should be component of multiple-risk-fact. intervent.in individ.at   710868-001: 10 mg, 30, R39,70
       to start.LDLcholestrol lev., treatm.aim & pt.respons. Do not admin.  risk of atherosclerot. vasc.dis. due to hypercholesterolaem., lipid   710869-001: 20 mg, 30, R41,61
       with grapefruit juice.        low.agents used in addit. to diet restrict.in saturat.fat & cholesterol   710870-001: 40 mg, 30, R42,38
       Heterozygous famil.hypercholesterolaem.& mix.dyslipi-  only when response to diet & other non-pharmacolog.meas.inadeq.,   Dosage: Adhere to cholester.-low.diet bef.init.& dur.ther.
       daem: Usual start.dos: 10 mg dly. May be adjust.at interv.of 4  wks.  excl.second.caus.prior to init.ther., monit.liv.funct.bef.& dur.treatm.,   Hypercholesterolaem: Init.10 mg/day as sngl. dos.in even. Reduc.
       up to max.of 80 mg dly.       withdr. recomm.if incr.ser.transminas.&gt;3 ULN persist., interr.treatm.  dos.if LDL-cholester.lev.falls below 1,94 mmol/L or tot.plasma cho-
       Homozygous familial hypercholesterolaem: 10-80 mg once/day.   if ser.liver injur.with clin. sympts. &/or hyperbilirubinaem./jaund.oc-  lester.lev. falls below 3,6 mmol/L
       Use as an adjunct.to other lipid-lower.treatm.such as LDL apheres.  curs & do not restart if altern.aetiol.not found, substant. alcoh. con-  Coron.heart dis: Init. 20 mg/day as sngl.dos.in even. Adjust dos.
       or if such treatm. unavail.   sum., liv.dis.hist., discont.if CPK lev.are marked.elev.or if myopathy   if reqd.at interv.of not less than 4 wks.to a max.of 80 mg/day as
       Cardiovasc.complic.prevent: Usual dos: 10 mg once/day.  is diagn./susp., monit. pts. with hist.of ren.impairm.for skelet.musc.  sngl.dos. in even.
       Contraindications: Plann.pregn., safety & effic.in pregn.& lactat.  effs./ rhabdomyolys., advis.pt.to report unexpl.musc. pain/ tendern   Concom.ther: Bile acid sequestr: Admin.1 hr. bef./ 4 hrs.aft.
       not est., act.liv. dis./persist.unexpl. elev.ser. transaminas.exceed.3x   or weakn.esp.if accompan.by malaise/fev., temp.withdraw.recomm.  cholestyramine. Max. dly dos.of 10 mg recomm.with concom.nia-
       norm. value, Child-Pugh B & C liv.impairm., concom.rifampicin/  dur.fusidic acid ther., withdr.in ac./ser.condit.suggest.of a myopathy/   cin. Max.dly.dos. of 10 mg not to be exceed. with concom.diltiazem
       grapefruit juice/diltiazem.   risk fact.predispos.to ren.fail. developm. second.to rhabdomyolys,   or verapamil. Max.dly.dos.of 20 mg not to be exceed. with concom.
       Side effects: Bld dyscras., hypersens.incl. angioed./anaphylax.,   haemorrhagic. stroke pts.on entry appear.to be at incr.risk for recurr.   amiodarone or amlodipine.
       hypo-/hyperglycaem., weight gain, anorex., psych./CNS/eye disords.,   haemorrhagic stroke, OC, HbA1c & fast. ser. gluc.incr., monit.con-  Contraindications: Ac./chron.liv.dis., unexpl. persist.ser.transami-
       dizzin., headache, paraesthes., periph.neuropathy, cognit./ memory   com.warfar., lact.intol.  nas.elev., safety in pregn.& lactat./ porphyr.not est., concom.strong
       impair., blurr.vis., tinnit., hear.loss, periph. oed., sinusit., pharyngit.,   Drug interactions: Myopathy risk incr.with concom. immunosup-  CYP3A4 inhibits./ gemfibrozil/ciclospor./danazol, safety & effic.in
       GI disturbs., pancreatit., hepatit., hepat.fail., cholestat.jaund., skin   press.agents incl.cyclospor./ fibric acid derivat./nicotin.acid/azole   paed.pts.not est., lact.intol., female pts.of child-bear. potent.
       reacts. incl. erythema multiforme/Stev.John.syndr./tox. epiderm.   antifung.or macrolide antibiot./colchicine & cytochrome P450 3A4   Side effects: Endocrine/psych.disords., diab. mellit., GI disturbs.,
       necrolys., arthralg., myalg., back/chest pain, myopathy, rhabdomy-  inhibits., inhibits. of OATP1B1 e.g. ciclosporin incr. bioavail., erythro-  pancreatit., resp.infect., interstit. lung dis., bronchit., sinusit., bld. dys-
       olys.with/without ren. impairm., miosit., musc.cramps, tend.rupt.,   mycin/clarithromycin/ grapefruit juice incr.plasma conc., cytochrome   cras., UTI, erect.dysfunct., skin reacts.incl.tox. epiderm. necrolys./ery-
       impot., gynaecomast., fatig., asthen., infect., malaise.  P450 3A4 induc.reduc.plasma conc., incr.plasma conc. with protease   thema multiforme/Stev. Johns. syndr., alopec., myalg., musc.cramps,
       Special precautions: Excl.second.caus.& meas. lipid profile   inhibit./cytochrome P450 3A4 inhibitors/ combinats. of HIV protease   myopathy, myositis, arthralg., rhabdomyolys.incl. fatalit., tendino-
       prior to init.ther., chron. alcoh.liv.dis., substant. alcoh.consum., ren.  inhibits., incr. AUC with diltiazem/itraconazole, oral antacids con-  path., CNS effs., headache, periph. neuropathy, dizzin., paraesthes.,
       impairm.hist., monit. liv.funct.bef.& dur.treatm., predispos.to devel.  tain Mg & Al decr.plasma conc., plasma conc.decr.with colestipol   atrial fibrillat., hypersens.reacts.incl.lupus-like syndr./ anaphylax./
       ren. fail. second.to rhabdomyolys., meds.relat.mark. CK conc. incr.,   although LDLC reduct.was great.in combin.than when either med   fev./dyspn., mass gain, asthen., fatig., oed., swell., hepatit., jaund.,
       rhabdomyolys.risk, concom.cytochrome P450 inhibits./warfar., not   was giv. alone, steady-state plasma conc.of digox. incr., AUC values   hepat.fail., cognit.impairm., immune-mediat. necrotis. myopathy.
       for lact.intol.indiv., discont. if ALT & AST persist.&gt;3 times ULN, monit.   of norethindrone & ethinyl estradiol incr.  Warnings and special precautions: High risk of future diab.
       with fucid.acid, admin.1 hr.bef./4 hrs.aft. cholestyramin., discont.if   LIPOGEN, Ranbaxy [P/S]  mellit., fetotox.& teratogen.in animals, sev.ren.insuff., predispos.
       CPK lev.mark.elev.or if myopathy diagn., cons.benef.vs. risk with   Atorvastatin.  rhabdomyolys. fact., avoid grapefr.juice dur. treatm., INR monit.with
       concom. immunosuppress./fibrat./lipid-lower.niacin dos., concom.   Indications: Adjunct.to diet for reduc.of elev.tot.-cholesterol, LDL-  coumarin anticoags., concom. fusid.acid not recomm., high.myo-
       itraconazole/ ketoconazole/erythromycin/ clarithromycin/ HIV-prot.  cholestrol, apolipoprotein-B & triglyceride levs.in pts.with prim.   pathy/ rhabdomyolys.risk in Chinese pts.with concom. lipid-lower.
       inhibits./nefazodone not recomm., discont.ther.tempor.in case of   hypercholesterolaem. / mix.dyslipidaem.& heterozygous familial   niacin dos., discont.ther.if interstit. lung dis.susp./unexpl.musc.pain/
       concom. ciclospor., stroke without.coron.heart dis./TIA, haemorrh.   hypercholesterolaem., adjunct to diet to reduc.total-C, LDL-C in ho-  tendern./ weakn. report./myopathy susp./occurs/musc. sympt.sev.&
       stroke hist., safety & effic.in paed.pts. not est., adeq.contracept.ad-  mozygous familial hypercholesterolaem.as adjunct to other lipid low.  caus.dly.discomf., concom.meds. known to be mod.CYP3A4 inhibits.,
       vis.in women of childbear. potent., allow 1 mnth.interv.aft.discont.   treatm.or if such treatm. unavail.  substant. alcoh.consumpt.&/liv.dis.hist., LFT advis. bef.init. treatm.&
       ther. bef.plann. pregn.       (S4) TABS. 42/7.5/0556, 0557, 0558, 0559  thereaft.if clinic.indic., interr.ther.if ser. liv. inj.with clinic.sympt.&/ hy-
       Interactions: Incr.plasma conc.with cytochrome P450 3A4 inhib-  714071-001: 10 mg, 30, R33,90  perbilirubinaem./ jaund. occurs, outweigh benef.-risk with concom.
       its.& grapefr.juice, incr AUC with diltiazem, sev.musc.probl.with   714072-001: 20 mg, 30, R36,03  lipid. low.niacin/where predispos.fact.for rhabdomyolys. exist, pre-
       fucid.acid, incr. bioavailabil.with OATP1B1 transport syst.inhibits.,   714073-001: 40 mg, 30, R63,05  disposit.to develop. ren.fail. second.to rhabdomyolys., incr.myopathy
       incr. warfar.anticoag.eff., elev.in ser.digox.conc., decr. bioavail.with   714074-001: 80 mg, 30, R114,57  risk with concom.other meds.caus.myopathy.
       cholestyramin., azole antifung./ ciclospor./gemfibozil/other fibrat./   Dosage: Init.& contin.diet ther.bef.& dur.treatm.  Drug interactions: Meds.inhibit.P450 CYP3A4 poss.incr.plasma
       immunosuppress./ macrolide antibiot./niacin assoc. with incr.myo-  Init.10 mg once dly. Adjust dos.only aft.4 wks.or more. Max.recomm.  lev.incr.myopathy & rhabdomyolys. risk, incr.myopathy risk incl.fa-
       pathy/miosit./rhabdomyolys. /ac. ren.fail.risk, decr.plasma conc.with   dos.depend.on indicat.   talit. with fusid.acid, &gt; 1 lit./day grapefruit juice incr. expos., digoxin
       antacids, incr. norethindrone/ethinyl oestrad.AUC, incr. plasma conc.  Prim.hypercholesterolaem.& combin.(mix.) hyperlipidaem:   lev.incr., anticoag.eff.of coumar. anticoags. incr., bile acid sequestr.
       with erythromycin/clarithromycin, reduc. plasma conc.with cert.cyto-  10 mg once dly. Therap.response within 2 wks.& max.respons.  decr.bioavail., poss. reduc.effic.with rifampicin, incr.myopathy/ rhab-
       chrome P450 3A4 induc./ rifampicin.  within 4 wks.         domyolys. risk with amlodipine/amiodarone as well as with concom.
       LIPITOR, Pfizer [P/S]         Heterozygous familial hypercholesterolaem.: Init.10 mg dly.   colchicine in pts.with ren. impairm.
                                     Max.recomm.dos: 20 mg.
       Atorvastatin calcium          Homozygous familial hypercholesterolaem: Most pts.re-  PIXETA, Accord [P/S]
       Indications: Adjunct.to diet for reduc.of elev.tot.-cholesterol, LDL-  spond to 80 mg.  Pravastatin sod.
       cholestrol, apolipoprotein-B, triglyceride levs. & to moderat.incr.   Contraindications: Act.liv.dis./persist.unexplain elev.ser.transam-  Indications: In hypercholesterolaem.pts. without clinic. evid.coron.
       HDL-cholesterol in pts.with prim.hypercholesterolaem. & combin./  inas., pregn., safety & effic.in childr. not est., concom.rifampicin/  heart dis.to reduc.MI risk/reduc. risk of undergoing myocard.revascu-
       mix.dyslipidaem., to reduc. total-C and LDL-C in homozygous familial   diltiazem & grapefruit juice, Child-Pugh B & C (liv.cirrhosis), heredit.ga-  larizat.proced./ reduc. CV mortality riskwith no incr.in death from non-
       hypercholesterolaem. as adjunt.to other lipid low. treatm.or if such   lactose intol./Lapp lactase defic/gluc-galact.malabsorpt., breastfeed.,   CV causes, in hypercholesterolaem.pts.with clinic. evid.coron.heart
       treatm.unavail., adjunct to diet to reduc.total-C, LDL-C & apo B levs   women of childbear. potent.unless adeq.contracept.precaut. taken.  dis.incl.prior MI to slow. progress. of coron.atheroscleros.& reduc.
       in boys & postmenarch. girls &gt;10-17 yrs with heterozygous familial   Side effects: Rhabdomyolys.with/without ren. impairm., myalgia,   risk of ac. coron. events,with prev.MI & norm.cholester.lev. to reduc.
       hypercholesterolaem.if aft.an adeq.trial of diet ther.LDL-C remains ≥   myopathy, insomn., headache, GI disords., asthen., hypo./hyper-  risk of recurr.MI/reduc. risk of undergo. myocard. revascularizat.pro-
       190 mg/dL(4,98 mmol/L) or LDL-C remains ≥160 mg/dL(4,04 mmol/L   glycaem., periph. neuropathy, paraesthes., pancreatit., cholestat.   ced./reduc.risk of stroke or TIA’s, In combinat.with diet to reduc.elev.
       & positiv. family hist of premat.CV dis.or 2 or more other CVD risk   jaund., rash, alopec., prurit., myosit., musc.cramps, impot., thrombo-  ser. tot.cholesterol & LDL cholesterol in prim. hypercholesterolaem.
       facts pres.in paed.pts., reduc.risk of ischaem.CV & cerebrovasc.dis.  cytopaen., allerg.reacts.incl. anaphylax., weight gain, hypoaesthes.,   (S4) TABS, 42/7.5/0372, 0373, 0358
       in pts.without clinic. evid.CV dis.& with/without dyslipidem.but with   dizzin., amnes., tinnit., Stev.John.syndr., tox.epiderm. necrolys., ery-  715709-001: 10 mg, 30, R160,47
       multiple risk factors for coron.heart dis., second. reduct.of cardiovasc.   them.multiforme., bullous rash, urticar., arthralg., chest & back pain,   715710-001: 20 mg, 30, R175,82
       events.in pts.with clinic. evid. coron.heart dis.& incr.cholestr.levs.  malaise., periph.oed.,  715711-001: 40 mg, 30, R242,24
       (S4) TABS. 31/7.5/0357, 0358, 0359, 37/7.5/0210  Special precautions: Ther.with lipid lower. agents should be com-  Dosage: In combinat.with cholesterol-low. diet. Effect.enhanc.in
       831484-006: 10 mg, 30, R273,19  ponent of multiple-risk-fact. intervent.in individ.at risk of atherosclerot.   combinat.with bile acid bind.resin.
       831492-008: 20 mg, 30, R424,64  vasc. dis.due to hypercholesterolaem., use in addit.to diet restrict.only   Adults:
       886015-008: 40 mg, 30, R424,65  when response to diet & other non-pharmacologic. meas.inadeq.,   Hypercholesterolaem: 10 mg/day as sngl.even. dos. Reduc.if LDL-
       704186-001: 80 mg, 30, R424,64  excl.second. caus. prior to init.ther., monit.liv.funct.bef.& dur. treatm.,   cholesterol falls bel.1,94 mmol /L or tot.plasma chol.lev.fall bel.3,6
       Dosage: Init.& contin.diet ther.bef.& dur.treatm.  withdr.if ALT & AST incr.&gt;3 times ULN persist, substant.alcoh.con-  mmol/L. If ser. cholesterol mark.elev.may init.at 40 mg/day.
       Init.10 mg once dly. indiv. accord. to baseline LDL-C lev/ goal of ther.   sum., liv.dis.hist., discont. if CPK lev.are marked.elev.or if myopathy   Cor.heart dis: Init. 20 mg/day as sngl.even. dos. Max.eff.seen within
       & pt. resp. Adjust dos.only aft.4 wks.or more. Max.recomm.dos: De-  is diagn./susp., withdr.in ac./ser.condit.suggest.of a myopathy/having   4 wks. Dos.range: 10 mg to max.40 mg once dly.at bedt.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page161.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page157.html">157</a>&nbsp;&nbsp;&nbsp;<a href="page158.html">158</a>&nbsp;&nbsp;&nbsp;<a href="page159.html">159</a>&nbsp;&nbsp;&nbsp;<a href="page160.html">160</a>&nbsp;&nbsp;&nbsp;<a href="page161.html">161</a>&nbsp;&nbsp;&nbsp;<a href="page162.html">162</a>&nbsp;&nbsp;&nbsp;<a href="page163.html">163</a>&nbsp;&nbsp;&nbsp;<a href="page164.html">164</a>&nbsp;&nbsp;&nbsp;<a href="page165.html">165</a>&nbsp;&nbsp;&nbsp;<a href="page166.html">166</a>&nbsp;&nbsp;&nbsp;<a href="page167.html">167</a>
             </td>
             <td width="35%"><a href="page163.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page163.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
